Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer
NCT07730151Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2031
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Renji Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07730151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730151.